Figure 1From: Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patientsKinetic of Anti EGF antibodies and serum EGF concentrations in the Phase III Trial (Vaccination with high dose/4 anatomic sites). The anti-EGF antibody titer was inversely correlated to the EGF serum concentration (spearman r correlation, p < 0.05). in this high dose/multiple sites study the decay below the 500 pg/mL threshold had effect after 76 days of vaccination.Back to article page